Literature DB >> 22015921

Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Mark E Lobatto1, Valentin Fuster, Zahi A Fayad, Willem J M Mulder.   

Abstract

The use of nanotechnology for medical purposes--nanomedicine--has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.

Entities:  

Mesh:

Year:  2011        PMID: 22015921      PMCID: PMC3623275          DOI: 10.1038/nrd3578

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  184 in total

1.  Forkhead transcription factors inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia.

Authors:  Md Ruhul Abid; Kiichiro Yano; Shaodong Guo; Virendra I Patel; Gautam Shrikhande; Katherine C Spokes; Christiane Ferran; William C Aird
Journal:  J Biol Chem       Date:  2005-06-15       Impact factor: 5.157

2.  Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging.

Authors:  Denis B Buxton; Melissa Antman; Narasimhan Danthi; Vasken Dilsizian; Zahi A Fayad; Mario J Garcia; Michael R Jaff; Michael Klimas; Peter Libby; Matthias Nahrendorf; Albert J Sinusas; Samuel A Wickline; Joseph C Wu; Robert O Bonow; Ralph Weissleder
Journal:  Circulation       Date:  2011-05-17       Impact factor: 29.690

Review 3.  Atherosclerotic lesions in mouse and man: is it the same disease?

Authors:  Jacob Fog Bentzon; Erling Falk
Journal:  Curr Opin Lipidol       Date:  2010-10       Impact factor: 4.776

4.  Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields.

Authors:  Michael Chorny; Ilia Fishbein; Benjamin B Yellen; Ivan S Alferiev; Marina Bakay; Srinivas Ganta; Richard Adamo; Mansoor Amiji; Gary Friedman; Robert J Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

5.  Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles.

Authors:  David P Cormode; Ewald Roessl; Axel Thran; Torjus Skajaa; Ronald E Gordon; Jens-Peter Schlomka; Valentin Fuster; Edward A Fisher; Willem J M Mulder; Roland Proksa; Zahi A Fayad
Journal:  Radiology       Date:  2010-07-28       Impact factor: 11.105

Review 6.  Macrophage death and defective inflammation resolution in atherosclerosis.

Authors:  Ira Tabas
Journal:  Nat Rev Immunol       Date:  2009-12-04       Impact factor: 53.106

7.  Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries.

Authors:  Sanjay Kaul; Vladimir Rukshin; Raul Santos; Babak Azarbal; Charles L Bisgaier; Jan Johansson; Vivian T Tsang; Kuang-Yuh Chyu; Bojan Cercek; James Mirocha; Prediman K Shah
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

Review 8.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-07       Impact factor: 29.690

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

View more
  112 in total

Review 1.  Approaching the asymptote: obstacles and opportunities for nanomedicine in cardiovascular disease.

Authors:  Sascha N Goonewardena
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  Nanoparticle-Delivered IRF5 siRNA Facilitates M1 to M2 Transition, Reduces Demyelination and Neurofilament Loss, and Promotes Functional Recovery After Spinal Cord Injury in Mice.

Authors:  Jun Li; Yanbin Liu; Haidong Xu; Qiang Fu
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

Review 3.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

4.  Monocyte-targeting supramolecular micellar assemblies: a molecular diagnostic tool for atherosclerosis.

Authors:  Eun Ji Chung; Laurie B Mlinar; Kathryn Nord; Matthew J Sugimoto; Emily Wonder; Francis J Alenghat; Yun Fang; Matthew Tirrell
Journal:  Adv Healthc Mater       Date:  2014-08-22       Impact factor: 9.933

Review 5.  Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems.

Authors:  Daniel J Sobczynski; Margaret B Fish; Catherine A Fromen; Mariana Carasco-Teja; Rhima M Coleman; Omolola Eniola-Adefeso
Journal:  Ther Deliv       Date:  2015-08-14

6.  Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.

Authors:  Xue-Qing Zhang; Orli Even-Or; Xiaoyang Xu; Mariska van Rosmalen; Lucas Lim; Suresh Gadde; Omid C Farokhzad; Edward A Fisher
Journal:  Adv Healthc Mater       Date:  2014-08-22       Impact factor: 9.933

7.  Making things stick in the fight against atherosclerosis.

Authors:  Ira Tabas
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

8.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

Review 9.  Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery.

Authors:  Weiwei Gao; Yue Zhang; Qiangzhe Zhang; Liangfang Zhang
Journal:  Ann Biomed Eng       Date:  2016-03-07       Impact factor: 3.934

Review 10.  Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases.

Authors:  William J Kelley; Hanieh Safari; Genesis Lopez-Cazares; Omolola Eniola-Adefeso
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.